Barclays’s NovoCure NVCR Stock Holding History

Barclays’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,000	Closed	-$894K	–	5458
2024 Q4	$894K	Buy	+30,000	New	+$635K	﹤0.01%	3449
2022 Q1	–	Sell	-1,900	Closed	-$143K	–	5428
2021 Q4	$143K	Buy	1,900 +1,300	+217%	+$130K	﹤0.01%	3652
2021 Q3	$70K	Buy	+600	New	+$90.7K	﹤0.01%	4024
2021 Q1	–	Sell	-17,400	Closed	-$3.01M	–	5044
2020 Q4	$3.01M	Hold	17,400	–	–	﹤0.01%	1922
2020 Q3	$1.94M	Sell	17,400 -20,000	-53%	-$1.6M	﹤0.01%	2131
2020 Q2	$2.22M	Sell	37,400 -30,000	-45%	-$1.97M	﹤0.01%	2027
2020 Q1	$4.54M	Buy	67,400 +47,700	+242%	+$3.77M	﹤0.01%	1545
2019 Q4	$1.66M	Buy	19,700 +10,200	+107%	+$823K	﹤0.01%	3194
2019 Q3	$710K	Sell	9,500 -100,000	-91%	-$8M	﹤0.01%	3956
2019 Q2	$6.92M	Buy	109,500 +9,500	+10%	+$481K	﹤0.01%	1583
2019 Q1	$4.82M	Buy	+100,000	New	+$4.81M	﹤0.01%	1691

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Barclays's NVCR Position: Q1 2026 in Review

Barclays reduced its NovoCure (NVCR) stake by 34% in Q1 2026, selling an estimated $1.87M and leaving 297,416 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Barclays first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $42.2M in Q4 2019. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Barclays held 297,416 shares of NovoCure worth $3.24M as of Q1 2026.
Barclays sold 149,839 NovoCure shares in Q1 2026, an estimated $1.87M.
NovoCure made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2078 holding.
Barclays first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
Barclays's NovoCure position peaked at $42.2M in Q4 2019.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.